Acute Myeloid Leukemia with the t(8;21) Translocation: Clinical Consequences and Biological Implications
暂无分享,去创建一个
Håkon Reikvam | Øystein Bruserud | Ø. Bruserud | H. Reikvam | R. Hovland | A. Kittang | K. Hatfield | Kimberley Joanne Hatfield | Astrid Olsnes Kittang | Randi Hovland
[1] C. Klug,et al. Differential Contributions of c-Kit Activating Mutations to Promotion of AML1-ETO Associated Neoplasia , 2010 .
[2] R. Hills,et al. OGG1 is a novel prognostic indicator in acute myeloid leukaemia , 2010, Oncogene.
[3] Bob Löwenberg,et al. MicroRNA expression profiling in relation to the genetic heterogeneity of acute myeloid leukemia. , 2008, Blood.
[4] Y. Hayashi,et al. KIT mutations, and not FLT3 internal tandem duplication, are strongly associated with a poor prognosis in pediatric acute myeloid leukemia with t(8;21): a study of the Japanese Childhood AML Cooperative Study Group. , 2006, Blood.
[5] Ana-Teresa Maia,et al. In utero origin of t(8;21) AML1-ETO translocations in childhood acute myeloid leukemia. , 2002, Blood.
[6] Bas J. Wouters,et al. Prediction of molecular subtypes in acute myeloid leukemia based on gene expression profiling , 2009, Haematologica.
[7] W. Hiddemann,et al. New score predicting for prognosis in PML-RARA+, AML1-ETO+, or CBFBMYH11+ acute myeloid leukemia based on quantification of fusion transcripts. , 2003, Blood.
[8] Ming Yan,et al. The p21Waf1 pathway is involved in blocking leukemogenesis by the t(8;21) fusion protein AML1-ETO. , 2007, Blood.
[9] H. Dombret,et al. Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML) , 2006, Leukemia.
[10] J. Leavitt,et al. Activation of the leukocyte plastin gene occurs in most human cancer cells. , 1994, Cancer research.
[11] Guoqiang Chen,et al. AML1-ETO and C-KIT mutation/overexpression in t(8;21) leukemia: implication in stepwise leukemogenesis and response to Gleevec. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[12] T. Haferlach,et al. JAK2V617F as progression marker in CMPD and as cooperative mutation in AML with trisomy 8 and t(8;21): a comparative study on 1103 CMPD and 269 AML cases , 2007, Leukemia.
[13] H. Cavé,et al. Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia – A Europe Against Cancer Program , 2003, Leukemia.
[14] T. Golub,et al. Distinct microRNA expression profiles in acute myeloid leukemia with common translocations , 2008, Proceedings of the National Academy of Sciences.
[15] H. Klamová,et al. CEBPA polymorphisms and mutations in patients with acute myeloid leukemia, myelodysplastic syndrome, multiple myeloma and non-Hodgkin's lymphoma. , 2008, Blood cells, molecules & diseases.
[16] M. Drayson,et al. The co-expression of PML/RARa and AML1/ETO fusion genes is associated with ATRA resistance , 2005 .
[17] Rowley Jd. Identificaton of a translocation with quinacrine fluorescence in a patient with acute leukemia. , 1973 .
[18] Danielle Boller,et al. Targeting receptor tyrosine kinase signaling in acute myeloid leukemia. , 2007, Critical reviews in oncology/hematology.
[19] J. Reilly,et al. Incidence and prognosis of c‐KIT and FLT3 mutations in core binding factor (CBF) acute myeloid leukaemias , 2003, British journal of haematology.
[20] M. Esteller. Epigenetics in cancer. , 2008, The New England journal of medicine.
[21] E. Estey,et al. Comparison of outcome in acute myelogenous leukemia patients with translocation (8;21) found by standard cytogenetic analysis and patients with AML1/ETO fusion transcript found only by PCR testing , 2001, Leukemia.
[22] C. Fonatsch,et al. Myelomastocytic Leukemia: Evidence for the Origin of Mast Cells from the Leukemic Clone and Eradication by Allogeneic Stem Cell Transplantation , 2005, Clinical Cancer Research.
[23] D. Gold,et al. Novel role of HDAC inhibitors in AML1/ETO AML cells: activation of apoptosis and phagocytosis through induction of annexin A1 , 2007, Cell Death and Differentiation.
[24] S. Bohlander,et al. Proteomics of acute myeloid leukaemia: cytogenetic risk groups differ specifically in their proteome, interactome and post-translational protein modifications , 2006, Oncogene.
[25] P. Hokland,et al. Multiplex reverse transcription-polymerase chain reaction for simultaneous screening of 29 translocations and chromosomal aberrations in acute leukemia. , 1998, Blood.
[26] M. Rocchi,et al. Insertions generating the 5′RUNX1/3′CBFA2T1 gene in acute myeloid leukemia cases show variable breakpoints , 2004, Genes, chromosomes & cancer.
[27] S. Ogston,et al. Population-based demographic study of karyotypes in 1709 patients with adult Acute Myeloid Leukemia , 2006, Leukemia.
[28] K. Tobal,et al. Diagnosis and monitoring of AML1-MTG8 (ETO)-positive acute myeloid leukemia by qualitative and real-time quantitative RT-PCR. , 2006, Methods in molecular medicine.
[29] A. Hagemeijer,et al. Translocation (8;17;15;21)(q22;q23;q15;q22) in acute myeloid leukemia (M2). a four-way variant of t(8;21). , 2001, Cancer genetics and cytogenetics.
[30] K. Tanriverdi,et al. PRAME mRNA levels in cases with acute leukemia: Clinical importance and future prospects , 2005, American journal of hematology.
[31] S. Meshinchi,et al. Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia , 2005, Leukemia.
[32] E. Macintyre,et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease , 1999, Leukemia.
[33] L. Bullinger,et al. Mutations in the Fms-Related Tyrosine Kinase 3 (FLT3) Gene Independently Predict Poor Outcome in Acute Myeloid Leukemia (AML) with t(8;21): A Study of the German-Austrian AML Study Group (AMLSG). , 2009 .
[34] J. Downing,et al. Characteristics and outcome of t(8;21)-positive childhood acute myeloid leukemia: a single institution's experience , 2002, Leukemia.
[35] Ø. Bruserud,et al. Review: genetic models of acute myeloid leukaemia , 2008, Oncogene.
[36] Y. Bertrand,et al. Results of 58872 and 58921 trials in acute myeloblastic leukemia and relative value of chemotherapy vs allogeneic bone marrow transplantation in first complete remission: the EORTC Children Leukemia Group report , 2005, Leukemia.
[37] Amit Verma,et al. AML1-ETO Decreases ETO-2 (MTG16) Interactions with Nuclear Receptor Corepressor, an Effect That Impairs Granulocyte Differentiation , 2004, Cancer Research.
[38] J. Esteve,et al. Outcome of patients with acute promyelocytic leukemia failing to front-line treatment with all-trans retinoic acid and anthracycline-based chemotherapy (PETHEMA protocols LPA96 and LPA99): benefit of an early intervention , 2007, Leukemia.
[39] L. Roudaia,et al. CBFbeta is critical for AML1-ETO and TEL-AML1 activity. , 2009, Blood.
[40] M. Ikura,et al. The acute myeloid leukemia fusion protein AML1-ETO targets E proteins via a paired amphipathic helix-like TBP-associated factor homology domain , 2006, Proceedings of the National Academy of Sciences.
[41] C. Auewarakul,et al. KIT and FLT3 receptor tyrosine kinase mutations in acute myeloid leukemia with favorable cytogenetics: two novel mutations and selective occurrence in leukemia subtypes and age groups. , 2008, Experimental and molecular pathology.
[42] M. Slovak,et al. Prognostic Impact of Acute Myeloid Leukemia Classification , 2003 .
[43] J. Foran. New prognostic markers in acute myeloid leukemia: perspective from the clinic. , 2010, Hematology. American Society of Hematology. Education Program.
[44] Guoqiang Chen,et al. Leukemogenic AML1-ETO fusion protein increases carcinogen-DNA adduct formation with upregulated expression of cytochrome P450-1A1 gene. , 2007, Experimental hematology.
[45] S. K. Zaidi,et al. The leukemogenic t(8;21) fusion protein AML1-ETO controls rRNA genes and associates with nucleolar-organizing regions at mitotic chromosomes , 2008, Journal of Cell Science.
[46] Zheng Zhao,et al. Delineation of the minimal commonly deleted segment and identification of candidate tumor‐suppressor genes in del(9q) acute myeloid leukemia , 2005, Genes, chromosomes & cancer.
[47] T. Cierpicki,et al. Structure of the AML1-ETO eTAFH domain-HEB peptide complex and its contribution to AML1-ETO activity. , 2009, Blood.
[48] Ming Yan,et al. Disruption of the NHR4 domain structure in AML1-ETO abrogates SON binding and promotes leukemogenesis , 2008, Proceedings of the National Academy of Sciences.
[49] T. Hervig,et al. Combination of Intensive Chemotherapy and Anticancer Vaccines in the Treatment of Human Malignancies: The Hematological Experience , 2010, Journal of biomedicine & biotechnology.
[50] R. Paquette,et al. Systemic mastocytosis with plasma cell dyscrasia: report of a case. , 2008, Leukemia research.
[51] W. Hiddemann,et al. Evaluation of complete disease remission in acute myeloid leukemia , 2006, Cancer.
[52] D. Tenen,et al. The myeloid master regulator transcription factor PU.1 is inactivated by AML1-ETO in t(8;21) myeloid leukemia. , 2003, Blood.
[53] Bob Löwenberg,et al. Review Articles (434 articles) , 2008 .
[54] K. Akashi,et al. Persistence of multipotent progenitors expressing AML1/ETO transcripts in long-term remission patients with t(8;21) acute myelogenous leukemia. , 1996, Blood.
[55] R. Schlenk,et al. HLA-identical sibling allogeneic transplants versus chemotherapy in acute myelogenous leukemia with t(8;21) in first complete remission: collaborative study between the German AML Intergroup and CIBMTR. , 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[56] R. Mann,et al. The t(8;21) translocation converts AML1 into a constitutive transcriptional repressor , 2005, Development.
[57] R. Arceci,et al. Long-term results of children with acute myeloid leukemia: a report of three consecutive Phase III trials by the Children's Cancer Group: CCG 251, CCG 213 and CCG 2891 , 2005, Leukemia.
[58] Ming Yan,et al. Acute myeloid leukemia with the 8q22;21q22 translocation: secondary mutational events and alternative t(8;21) transcripts. , 2007, Blood.
[59] M. Labopin,et al. Identical outcome after autologous or allogeneic genoidentical hematopoietic stem-cell transplantation in first remission of acute myelocytic leukemia carrying inversion 16 or t(8;21): a retrospective study from the European Cooperative Group for Blood and Marrow Transplantation. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[60] S. Rafii,et al. Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration. , 2000, The Journal of clinical investigation.
[61] T. Kyo,et al. Low p53 expression of acute myelocytic leukemia cells with t(8;21) chromosome abnormality: association with low p14(ARF) expression. , 2006, Leukemia research.
[62] C. Volteau,et al. Allogeneic hematopoietic stem-cell transplantation for myeloid sarcoma: a retrospective study from the SFGM-TC. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[63] L. Medeiros,et al. Acute myeloid leukemia harboring t(8;21)(q22;q22): a heterogeneous disease with poor outcome in a subset of patients unrelated to secondary cytogenetic aberrations , 2008, Modern Pathology.
[64] Ø. Bruserud,et al. Nuclear factor-kappaB signaling: a contributor in leukemogenesis and a target for pharmacological intervention in human acute myelogenous leukemia. , 2009, Critical reviews in oncogenesis.
[65] J. Taub,et al. Association between prenatal pesticide exposures and the generation of leukemia‐associated T(8;21) , 2007, Pediatric blood & cancer.
[66] W. Au,et al. Caveolin-1 gene is coordinately regulated with the multidrug resistance 1 gene in normal and leukemic bone marrow. , 2004, Leukemia research.
[67] Y. Kodera,et al. Hematopoietic stem cell transplantation for core binding factor acute myeloid leukemia: t(8;21) and inv(16) represent different clinical outcomes. , 2009, Blood.
[68] Manuela Zucknick,et al. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[69] L. Side,et al. Del (9q) AML: clinical and cytological characteristics and prognostic implications , 2005, British journal of haematology.
[70] W. Hiddemann,et al. The AML1-ETO fusion gene and the FLT3 length mutation collaborate in inducing acute leukemia in mice. , 2005, The Journal of clinical investigation.
[71] Ming Yan,et al. A leukemia fusion protein attenuates the spindle checkpoint and promotes aneuploidy. , 2007, Blood.
[72] J. A. Yunes,et al. Prognostic significance of WT1 gene expression in pediatric acute myeloid leukemia , 2007, Pediatric blood & cancer.
[73] F. Lo‐Coco,et al. Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[74] J. Byrd,et al. Interplay of RUNX1/MTG8 and DNA methyltransferase 1 in acute myeloid leukemia. , 2005, Cancer research.
[75] P. Andreassen,et al. p53 signaling in response to increased DNA damage sensitizes AML1-ETO cells to stress-induced death. , 2007, Blood.
[76] J. Pollack,et al. KIT mutations confer a distinct gene expression signature in core binding factor leukaemia , 2010, British journal of haematology.
[77] Hartmut Döhner,et al. Acute myeloid leukaemia , 2006, The Lancet.
[78] David Gillis,et al. The role of multiparameter flow cytometry for detection of minimal residual disease in acute myeloid leukemia. , 2009, American journal of clinical pathology.
[79] Håkon Reikvam,et al. Future Perspectives: Therapeutic Targeting of Notch Signalling May Become a Strategy in Patients Receiving Stem Cell Transplantation for Hematologic Malignancies , 2010, Bone marrow research.
[80] I. Weissman,et al. AML1-ETO expression is directly involved in the development of acute myeloid leukemia in the presence of additional mutations , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[81] N. Stergiopulos,et al. Gelsolin superfamily proteins: key regulators of cellular functions , 2004, Cellular and Molecular Life Sciences CMLS.
[82] M. Shikami,et al. t(8;21) acute myeloid leukaemia cells are dependent on vascular endothelial growth factor (VEGF)/VEGF receptor type2 pathway and phosphorylation of Akt , 2006, British journal of haematology.
[83] C. Bloomfield,et al. Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[84] P. Cahan,et al. POU4F1 is associated with t(8;21) acute myeloid leukemia and contributes directly to its unique transcriptional signature , 2010, Leukemia.
[85] H. Drabkin,et al. Identification of breakpoints in t(8;21) acute myelogenous leukemia and isolation of a fusion transcript, AML1/ETO, with similarity to Drosophila segmentation gene, runt. , 1992, Blood.
[86] R. Tibshirani,et al. Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. , 2004, The New England journal of medicine.
[87] R. Siebert,et al. DNA Methylation Profiles and Their Relationship with Cytogenetic Status in Adult Acute Myeloid Leukemia , 2010, PloS one.
[88] M. Caligiuri,et al. Persistence of the AML1/ETO fusion transcript in patients treated with allogeneic bone marrow transplantation for t(8;21) leukemia. , 1996, Blood.
[89] Fabien Campagne,et al. DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. , 2010, Cancer cell.
[90] H. Dombret,et al. A white blood cell index as the main prognostic factor in t ( 8 ; 21 ) acute myeloid leukemia ( AML ) : a survey of 161 cases from the French AML Intergroup , 2002 .
[91] Ming Yan,et al. A previously unidentified alternatively spliced isoform of t(8;21) transcript promotes leukemogenesis , 2006, Nature Medicine.
[92] C. Bloomfield,et al. Advances in molecular genetics and treatment of core-binding factor acute myeloid leukemia , 2008, Current opinion in oncology.
[93] B. Young,et al. A novel exon in AML1-ETO negatively influences the clonogenic potential of the t(8;21) in acute myeloid leukemia , 2010, Leukemia.
[94] H. Tamaki,et al. Molecular detection of AML1-MTG8-positive cells in peripheral blood from a patient with isolated extramedullary relapse of t(8;21) acute myeloid leukemia , 2009, Leukemia.
[95] P. Paschka,et al. Targeting AML1/ETO-Histone Deacetylase Repressor Complex: A Novel Mechanism for Valproic Acid-Mediated Gene Expression and Cellular Differentiation in AML1/ETO-Positive Acute Myeloid Leukemia Cells , 2007, Journal of Pharmacology and Experimental Therapeutics.
[96] T. Kalina,et al. Flow cytometric immunobead assay for the detection of BCR–ABL fusion proteins in leukemia patients , 2009, Leukemia.
[97] M. Čolović,et al. Granulocytic sarcoma of the brain in a patient with acute myeloid leukemia. , 2004, Acta chirurgica Iugoslavica.
[98] Hsien‐Kun Chang,et al. Therapy-Related Acute Myeloid Leukemia after Concurrent Chemoradiotherapy for Esophageal Cancer: Report of Two Cases , 2009, Tumori.
[99] K. Uozumi,et al. Two Cases of Secondary Acute Myeloid Leukemia Accompanying Adult T-Cell Leukemia/Lymphoma , 2007, International journal of hematology.
[100] J. Rowley,et al. Persistence of the 8;21 translocation in patients with acute myeloid leukemia type M2 in long-term remission. , 1993, Blood.
[101] M. Slovak,et al. Presence of t(8;21)(q22;q22) in myeloperoxidase-positive, myeloid surface antigen-negative acute myeloid leukemia. , 1997, American journal of clinical pathology.
[102] P. Rao,et al. Granulocytic Sarcoma Presenting as Pneumonia in a Child With t(8;21) Acute Myelogenous Leukemia: Diagnosis by Fluorescent In Situ Hybridization , 2004, Journal of pediatric hematology/oncology.
[103] Ming Yan,et al. Persistent altered fusion transcript splicing identifies RUNX1‐RUNX1T1+ AML patients likely to relapse , 2010, European journal of haematology.
[104] J. Downing,et al. The t(8;21) Fusion Product, AML-1–ETO, Associates with C/EBP-α, Inhibits C/EBP-α-Dependent Transcription, and Blocks Granulocytic Differentiation , 1998, Molecular and Cellular Biology.
[105] R. Verhaak,et al. Prognostically useful gene-expression profiles in acute myeloid leukemia. , 2004, The New England journal of medicine.
[106] J. Ahn,et al. Re-analysis of the outcomes of post-remission therapy for acute myeloid leukemia with core binding factor according to years of patient enrollment. , 2010, Japanese journal of clinical oncology.
[107] T. Hervig,et al. Connexins are active participants of hematopoietic stem cell regulation. , 2009, Stem cells and development.
[108] B. Davis,et al. Immunophenotypic profile predictive of KIT activating mutations in AML1-ETO leukemia. , 2007, American journal of clinical pathology.
[109] S. K. Zaidi,et al. Definitive hematopoiesis requires Runx1 C-terminal-mediated subnuclear targeting and transactivation. , 2010, Human molecular genetics.
[110] W. Hiddemann,et al. Cytogenetic profile in de novo acute myeloid leukemia with FAB subtypes M0, M1, and M2: a study based on 652 cases analyzed with morphology, cytogenetics, and fluorescence in situ hybridization. , 2004, Cancer genetics and cytogenetics.
[111] D. Tweardy,et al. Decreased intranuclear mobility of acute myeloid leukemia 1-containing fusion proteins is accompanied by reduced mobility and compartmentalization of core binding factor β , 2006, Oncogene.
[112] B. Gjertsen,et al. In vivo biological effects of ATRA in the treatment of AML. , 2008, Expert Opinion on Investigational Drugs.
[113] F. Lo‐Coco,et al. Epigenetic silencing of the myelopoiesis regulator microRNA-223 by the AML1/ETO oncoprotein. , 2007, Cancer cell.
[114] R K Craig,et al. Methods in molecular medicine. , 1987, British medical journal.
[115] J. Rowley,et al. Synergistic up-regulation of the myeloid-specific promoter for the macrophage colony-stimulating factor receptor by AML1 and the t(8;21) fusion protein may contribute to leukemogenesis. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[116] F. Behm,et al. Chromosomal abnormalities in 478 children with acute myeloid leukemia: clinical characteristics and treatment outcome in a cooperative pediatric oncology group study-POG 8821. , 1999, Blood.
[117] M. Grez,et al. Targeting the oligomerization domain of ETO interferes with RUNX1/ETO oncogenic activity in t(8;21)-positive leukemic cells. , 2007, Cancer research.
[118] Ø. Bruserud,et al. Connexin-based signaling in acute myelogenous leukemia (AML). , 2010, Biochimica et biophysica acta.
[119] Augustin Ferrant,et al. Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom? , 2007, Blood.
[120] Yipeng Wang,et al. Profiling of histone H3 lysine 9 trimethylation levels predicts transcription factor activity and survival in acute myeloid leukemia. , 2010, Blood.
[121] T. Naoe,et al. Clinical significance of minimal residual disease in patients with t(8;21) acute myeloid leukemia in Japan , 2008, International journal of hematology.
[122] S. K. Zaidi,et al. Altered Runx1 subnuclear targeting enhances myeloid cell proliferation and blocks differentiation by activating a miR-24/MKP-7/MAPK network. , 2009, Cancer research.
[123] S. Schnittger,et al. Strikingly different molecular relapse kinetics in NPM1c, PML-RARA, RUNX1-RUNX1T1, and CBFB-MYH11 acute myeloid leukemias. , 2010, Blood.
[124] W. Hiddemann,et al. Identification of additional cytogenetic and molecular genetic abnormalities in acute myeloid leukaemia with t(8;21)/AML1‐ETO , 2006, British journal of haematology.
[125] T. Cierpicki,et al. Structure of the AML1-ETO NHR3-PKA(RIIα) complex and its contribution to AML1-ETO activity. , 2010, Journal of molecular biology.
[126] C. Bloomfield,et al. A variant allele of Growth Factor Independence 1 (GFI1) is associated with acute myeloid leukemia. , 2007, Blood.
[127] F. Locatelli,et al. Treatment and long-term results in children with acute myeloid leukaemia treated according to the AIEOP AML protocols , 2005, Leukemia.
[128] Y. Hayashi,et al. Common gene expression signatures in t(8;21)‐ and inv(16)‐acute myeloid leukaemia , 2006, British journal of haematology.
[129] D. Gutmann,et al. Transcriptional Repression of the Neurofibromatosis-1 Tumor Suppressor by the t(8;21) Fusion Protein , 2005, Molecular and Cellular Biology.
[130] D. Liang,et al. Cooperating mutations of receptor tyrosine kinases and Ras genes in childhood core-binding factor acute myeloid leukemia and a comparative analysis on paired diagnosis and relapse samples , 2008, Leukemia.
[131] Guoqiang Chen,et al. Leukemogenic AML1‐ETO fusion protein upregulates expression of connexin 43: The role in AML1‐ETO‐induced growth arrest in leukemic cells , 2006, Journal of cellular physiology.
[132] L. Peterson,et al. t(8;21)(q22;q22) Fusion proteins preferentially bind to duplicated AML1/RUNX1 DNA-binding sequences to differentially regulate gene expression. , 2008, Blood.
[133] J. Zhang,et al. The AML1/ETO fusion protein activates transcription of BCL-2. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[134] J. Licht,et al. DNMT3A mutations in acute myeloid leukemia , 2011, Nature Genetics.
[135] T. Kyo,et al. Disease-specific expression of VEGF and its receptors in AML cells: possible autocrine pathway of VEGF/type1 receptor of VEGF in t(15;17) AML and VEGF/type2 receptor of VEGF in t(8;21) AML , 2006, Leukemia & lymphoma.
[136] Shiang Huang,et al. A correlation study of immunophenotypic, cytogenetic, and clinical features of 180 AML patients in China , 2008, Cytometry. Part B, Clinical cytometry.
[137] K. Tobal,et al. Detection of t(8;21) by reverse transcriptase polymerase chain reaction in patients in remission of acute myeloid leukaemia type M2 after chemotherapy or bone marrow transplantation. , 1994, Leukemia research.
[138] S. Pileri,et al. Myeloid sarcoma: clinico-pathologic, phenotypic and cytogenetic analysis of 92 adult patients , 2007, Leukemia.
[139] H. Gundacker,et al. The clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocations , 2006, British journal of haematology.
[140] N. Villamor,et al. Prognostic value of minimal residual disease (MRD) in acute myeloid leukemia (AML) with favorable cytogenetics [t(8;21) and inv(16)] , 2006, Leukemia.
[141] Guoqiang Chen,et al. c-Jun N-terminal kinase mediates AML1-ETO protein-induced connexin-43 expression. , 2007, Biochemical and biophysical research communications.
[142] F. Sigaux,et al. Evaluation of minimal residual disease using reverse-transcription polymerase chain reaction in t(8;21) acute myeloid leukemia: a multicenter study of 51 patients. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[143] U. Banerjee,et al. Genetic manipulation of AML1-ETO-induced expansion of hematopoietic precursors in a Drosophila model. , 2010, Blood.
[144] A. Venditti,et al. Comparison between conventional banding analysis and FISH screening with an AML-specific set of probes in 260 patients. , 2003, The hematology journal : the official journal of the European Haematology Association.
[145] C. Férec,et al. RUNX1 translocations and fusion genes in malignant hemopathies. , 2011, Future oncology.
[146] M. Wunderlich,et al. N-Ras(G12D) induces features of stepwise transformation in preleukemic human umbilical cord blood cultures expressing the AML1-ETO fusion gene. , 2011, Blood.
[147] M. Mancini,et al. Pericentric chromosome 8 inversion associated with the 5′RUNX1/3′CBFA2T1 gene in acute myeloid leukemia cases , 2005, Annals of Hematology.
[148] I. Bernstein,et al. Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML. , 2010, Blood.
[149] H. Dombret,et al. Acute myeloid leukemia with translocation (8;21) or inversion (16) in elderly patients treated with conventional chemotherapy: a collaborative study of the French CBF-AML intergroup. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[150] A. Cherry,et al. Utility of interphase FISH to stratify patients into cytogenetic risk categories at diagnosis of AML in an Eastern Cooperative Oncology Group (ECOG) clinical trial (E1900). , 2007, Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis.
[151] E. Al-Sobhi,et al. Granulocytic sarcoma causing cord compression in a pregnant woman with acute myeloid leukemia and t(8;21). , 2008, Saudi medical journal.
[152] M. Slovak,et al. Prognostic impact of acute myeloid leukemia classification. Importance of detection of recurring cytogenetic abnormalities and multilineage dysplasia on survival. , 2003, American journal of clinical pathology.
[153] R. Hills,et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. , 2010, Blood.
[154] Natalia Meani,et al. Acute myeloid leukemia fusion proteins deregulate genes involved in stem cell maintenance and DNA repair. , 2003, The Journal of clinical investigation.
[155] K. Döhner,et al. JAK2V617F mutations as cooperative genetic lesions in t(8;21)-positive acute myeloid leukemia. , 2006, Haematologica.
[156] M. Ferracin,et al. Differential cytogenomics and miRNA signature of the Acute Myeloid Leukaemia Kasumi-1 cell line CD34+38- compartment. , 2010, Leukemia research.
[157] O. Haas,et al. Prognostic impact of specific chromosomal aberrations in a large group of pediatric patients with acute myeloid leukemia treated uniformly according to trial AML-BFM 98. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[158] C. Preudhomme,et al. CEBPA point mutations in hematological malignancies , 2005, Leukemia.
[159] W. Hiddemann,et al. 1 KIT-D 816 mutations in AML 1-ETO positive AML are associated with impaired event-free and overall survival , 2005 .
[160] M. Slovak,et al. Neoplastic mast cells in systemic mastocytosis associated with t(8;21) acute myeloid leukemia are derived from the leukemic clone. , 2007, Leukemia research.
[161] Eva Tolosa,et al. Cathepsin W expressed exclusively in CD8+ T cells and NK cells, is secreted during target cell killing but is not essential for cytotoxicity in human CTLs. , 2009, Experimental hematology.
[162] S. Erkeland,et al. The gene encoding thioredoxin-interacting protein (TXNIP) is a frequent virus integration site in virus-induced mouse leukemia and is overexpressed in a subset of AML patients. , 2009, Leukemia research.
[163] M. Lin,et al. Cytogenetic profile of de novo acute myeloid leukemia: a study based on 1432 patients in a single institution of China , 2009, Leukemia.
[164] J. Stamatoyannopoulos,et al. Integrative Meta-Analysis of Differential Gene Expression in Acute Myeloid Leukemia , 2010, PloS one.
[165] M. Urioste,et al. Identification of ins(8;21) with AML1/ETO fusion in acute myelogenous leukemia M2 by molecular cytogenetics. , 2002, Cancer genetics and cytogenetics.
[166] Y. Kaneko,et al. MYND‐less splice variants of AML1–MTG8 (RUNX1–CBFA2T1) are expressed in leukemia with t(8;21) , 2005, Genes, chromosomes & cancer.
[167] J. Bennett,et al. Granulocytic sarcoma: A clinicopathologic study of 61 biopsied cases , 1981, Cancer.
[168] K. Mills,et al. Leukemia Associated Antigens: Their Dual Role as Biomarkers and Immunotherapeutic Targets for Acute Myeloid Leukemia , 2007, Biomarker insights.
[169] C. Preudhomme,et al. Prognostic value of real-time quantitative PCR (RQ-PCR) in AML with t(8;21) , 2005, Leukemia.
[170] B. Hug,et al. ETO interacting proteins , 2004, Oncogene.
[171] N. Kamada,et al. AML1-MTG8 leukemic protein induces the expression of granulocyte colony-stimulating factor (G-CSF) receptor through the up-regulation of CCAAT/enhancer binding protein epsilon. , 2000, Blood.
[172] L. Hood,et al. Analysis of acute myelogenous leukemia: preparation of samples for genomic and proteomic analyses. , 2002, Journal of hematotherapy & stem cell research.
[173] A. Ganser,et al. The oncogenic fusion protein RUNX1-CBFA2T1 supports proliferation and inhibits senescence in t(8;21)-positive leukaemic cells , 2004, BMC Cancer.
[174] Ming Yan,et al. RUNX1/AML1 DNA-binding domain and ETO/MTG8 NHR2-dimerization domain are critical to AML1-ETO9a leukemogenesis. , 2006, Blood.
[175] T. Taki,et al. Novel missense mutations in the tyrosine kinase domain of the platelet-derived growth factor receptor α(PDGFRA) gene in childhood acute myeloid leukemia with t(8;21)(q22;q22) or inv(16)(p13q22) , 2005, Leukemia.
[176] E. van den Berg,et al. Cytogenetics of childhood acute myeloid leukemia: United Kingdom Medical Research Council Treatment trials AML 10 and 12. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[177] J. Dausset,et al. Journal of Biomedicine and Biotechnology , 2001, Journal of biomedicine & biotechnology.
[178] M. Nelson,et al. Quantitative DNA methylation predicts survival in adult acute myeloid leukemia. , 2010, Blood.
[179] E. Estey,et al. Myeloid sarcoma is associated with superior event‐free survival and overall survival compared with acute myeloid leukemia , 2008, Cancer.
[180] G. Stein,et al. Altered chromatin modifications in AML1/RUNX1 breakpoint regions involved in (8;21) translocation , 2009, Journal of cellular physiology.
[181] J. Fontana,et al. Identification and characterization of novel AML1-ETO fusion transcripts in pediatric t(8;21) acute myeloid leukemia: a report from the Children's Oncology Group , 2008, Oncogene.
[182] G. Neufeld,et al. The semaphorins: versatile regulators of tumour progression and tumour angiogenesis , 2008, Nature Reviews Cancer.
[183] J. Friedl,et al. AML1/ETO fusion mRNA can be detected in remission blood samples of all patients with t(8;21) acute myeloid leukemia after chemotherapy or autologous bone marrow transplantation. , 1994, Leukemia.
[184] J. Reilly,et al. Cytogenetically cryptic AML1–ETO and CBFβ–MYH11 gene rearrangements: incidence in 412 cases of acute myeloid leukaemia , 2000, British journal of haematology.
[185] Hui Zhao,et al. AML1-ETO fusion protein up-regulates TRKA mRNA expression in human CD34+ cells, allowing nerve growth factor-induced expansion. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[186] T. Naoe,et al. Clinical characteristics and outcomes in patients with t(8;21) acute myeloid leukemia in Japan , 2007, Leukemia.
[187] Stefano Rossetti,et al. A distinct epigenetic signature at targets of a leukemia protein , 2007, BMC Genomics.
[188] A. Baruchel,et al. Treatment of childhood acute myeloblastic leukemia: dose intensification improves outcome and maintenance therapy is of no benefit – multicenter studies of the French LAME (Leucémie Aiguë Myéloblastique Enfant) Cooperative Group , 2005, Leukemia.
[189] W. Grody,et al. Systemic mastocytosis associated with t(8;21)(q22;q22) acute myeloid leukemia , 2009, Journal of hematopathology.
[190] C. Lelliott,et al. ETO/MTG8 Is an Inhibitor of C/EBPβ Activity and a Regulator of Early Adipogenesis , 2004, Molecular and Cellular Biology.
[191] W. Hiddemann,et al. Population-based age-specific incidences of cytogenetic subgroups of acute myeloid leukemia. , 2005, Haematologica.
[192] D. Rowe,et al. Diagnostic detection of AML1/ETO gene fusion by polymerase chain reaction , 2002, Leukemia.
[193] Ø. Bruserud,et al. Histone Deacetylase Inhibitors in Cancer Treatment: A Review of the Clinical Toxicity and the Modulation of Gene Expression in Cancer Cells , 2007 .
[194] A. Hagenbeek,et al. Minimal Residual Disease in Acute Leukemia , 1984, Developments in Oncology.
[195] Ø. Bruserud,et al. Flt3-mediated signaling in human acute myelogenous leukemia (AML) blasts: a functional characterization of Flt3-ligand effects in AML cell populations with and without genetic Flt3 abnormalities. , 2003, Haematologica.
[196] Claudio Lottaz,et al. Gene-expression profiling identifies distinct subclasses of core binding factor acute myeloid leukemia , 2007 .
[197] J. Rossi,et al. Good outcome of children with acute myeloid leukemia and t(8;21)(q22;q22), even when associated with granulocytic sarcoma , 2000, Cancer.
[198] A. Lier,et al. Preferred co-localization of chromosome 8 and 21 in myeloid bone marrow cells detected by three dimensional molecular cytogenetics. , 2009, International journal of molecular medicine.
[199] S. Mackinnon,et al. An unusual case of intrapulmonary granulocytic sarcoma presenting as interstitial pneumonitis following allogeneic bone marrow transplantation for acute myeloid leukaemia and responding to donor lymphocyte infusion , 1999, Bone Marrow Transplantation.
[200] K. Shitara,et al. Growth inhibition of AML cells with specific chromosome abnormalities by monoclonal antibodies to receptors for vascular endothelial growth factor. , 2009, Leukemia research.
[201] L. Medeiros,et al. Therapy-related acute myeloid leukemia with t(8;21) (q22;q22) shares many features with de novo acute myeloid leukemia with t(8;21)(q22;q22) but does not have a favorable outcome. , 2009, American journal of clinical pathology.
[202] O. Galm,et al. Heart and muscle involvement by extra-medullary myeloid leukemia: A case report and review of the literature , 2005, Leukemia & lymphoma.
[203] O. Heidenreich,et al. A Drosophila model identifies calpains as modulators of the human leukemogenic fusion protein AML1-ETO , 2009, Proceedings of the National Academy of Sciences.
[204] C. Bloomfield,et al. Clinical significance of the most common chromosome translocations in adult acute myeloid leukemia. , 2008, Journal of the National Cancer Institute. Monographs.
[205] Ø. Bruserud,et al. NewStrategies in the Treatment of Acute Myelogenous Leukemia: Mobilization and Transplantation of Autologous Peripheral Blood Stem Cells in Adult Patients , 2001, Stem cells.
[206] S. Pileri,et al. PAX5 Expression in Acute Leukemias , 2004, Cancer Research.
[207] F. Ferrara,et al. Total serum tryptase: a predictive marker for KIT mutation in acute myeloid leukemia. , 2009, Leukemia research.
[208] Xu-ping Liu,et al. Tetraploidy or near-tetraploidy clones with double 8;21 translocation: a non-random additional anomaly of acute myeloid leukemia with t(8;21)(q22;q22). , 2005, Haematologica.